Reporter brief
RCT of rapamycin and everolimus in older adults tested pharmacokinetics and pharmacodynamics of mTOR inhibition.
What happened
RESTOR was an exploratory pharmacokinetic/pharmacodynamic study that tested two mTOR inhibitors (rapamycin and everolimus) in healthy older adults. The study aimed to identify doses that could safely inhibit mTOR to levels seen in young people, with attention to potential sex differences in optimal dosing. No efficacy outcomes or clinical benefits were reported.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Healthy older adults, including both male and female subjects
- Design
- Rct
- Sample
- —
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Jun 1, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.